![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RPL10A |
Gene summary for RPL10A |
![]() |
Gene information | Species | Human | Gene symbol | RPL10A | Gene ID | 4736 |
Gene name | ribosomal protein L10a | |
Gene Alias | CSA19 | |
Cytomap | 6p21.31 | |
Gene Type | protein-coding | GO ID | GO:0000470 | UniProtAcc | P62906 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4736 | RPL10A | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 3.78e-54 | 1.95e+00 | -0.1433 |
4736 | RPL10A | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 4.02e-54 | 1.93e+00 | -0.1833 |
4736 | RPL10A | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 1.76e-26 | 3.31e+00 | -0.23 |
4736 | RPL10A | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 1.99e-26 | 3.32e+00 | -0.23 |
4736 | RPL10A | 047563_1562-all-cells | Human | Prostate | BPH | 2.48e-78 | -5.75e-01 | 0.0791 |
4736 | RPL10A | 048752_1579-all-cells | Human | Prostate | BPH | 1.06e-123 | -7.31e-01 | 0.1008 |
4736 | RPL10A | 052095_1628-all-cells | Human | Prostate | BPH | 3.32e-73 | -6.41e-01 | 0.1032 |
4736 | RPL10A | 052097_1595-all-cells | Human | Prostate | BPH | 4.19e-85 | -6.81e-01 | 0.0972 |
4736 | RPL10A | 052099_1652-all-cells | Human | Prostate | BPH | 1.09e-71 | -6.29e-01 | 0.1038 |
4736 | RPL10A | Dong_P3 | Human | Prostate | Tumor | 6.32e-25 | 1.66e-01 | 0.0278 |
4736 | RPL10A | P7 | Human | Prostate | Tumor | 1.67e-47 | 2.44e+00 | -0.1025 |
4736 | RPL10A | P9 | Human | Prostate | Tumor | 3.72e-10 | 7.59e-01 | -0.0285 |
4736 | RPL10A | P10 | Human | Prostate | Tumor | 1.89e-20 | 1.89e+00 | -0.0902 |
4736 | RPL10A | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 1.40e-09 | -4.94e-01 | 0.1557 |
4736 | RPL10A | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 4.30e-10 | -5.04e-01 | 0.159 |
4736 | RPL10A | GSM5353217_PA_PB1A_Pool_2_S107_L004 | Human | Prostate | Tumor | 1.53e-11 | -7.91e-01 | 0.156 |
4736 | RPL10A | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 2.87e-21 | -9.66e-01 | 0.1479 |
4736 | RPL10A | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 3.09e-22 | -8.89e-01 | 0.1531 |
4736 | RPL10A | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 2.75e-51 | -6.07e-01 | 0.1633 |
4736 | RPL10A | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.24e-52 | -5.57e-01 | 0.1608 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:004227310 | Cervix | CC | ribosomal large subunit biogenesis | 26/2311 | 72/18723 | 1.87e-07 | 8.48e-06 | 26 |
GO:002261310 | Cervix | CC | ribonucleoprotein complex biogenesis | 88/2311 | 463/18723 | 2.11e-05 | 3.82e-04 | 88 |
GO:004225410 | Cervix | CC | ribosome biogenesis | 62/2311 | 299/18723 | 2.48e-05 | 4.27e-04 | 62 |
GO:00973059 | Cervix | CC | response to alcohol | 46/2311 | 253/18723 | 4.40e-03 | 2.69e-02 | 46 |
GO:00160727 | Cervix | CC | rRNA metabolic process | 42/2311 | 236/18723 | 9.12e-03 | 4.60e-02 | 42 |
GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
GO:002261315 | Cervix | HSIL_HPV | ribonucleoprotein complex biogenesis | 52/737 | 463/18723 | 9.85e-12 | 6.81e-09 | 52 |
GO:004225415 | Cervix | HSIL_HPV | ribosome biogenesis | 40/737 | 299/18723 | 1.25e-11 | 6.81e-09 | 40 |
GO:004227315 | Cervix | HSIL_HPV | ribosomal large subunit biogenesis | 17/737 | 72/18723 | 1.94e-09 | 3.23e-07 | 17 |
GO:00063647 | Cervix | HSIL_HPV | rRNA processing | 27/737 | 225/18723 | 2.67e-07 | 1.55e-05 | 27 |
GO:001607215 | Cervix | HSIL_HPV | rRNA metabolic process | 27/737 | 236/18723 | 6.96e-07 | 3.57e-05 | 27 |
GO:00344706 | Cervix | HSIL_HPV | ncRNA processing | 27/737 | 395/18723 | 4.01e-03 | 3.45e-02 | 27 |
GO:000218125 | Cervix | N_HPV | cytoplasmic translation | 42/534 | 148/18723 | 2.61e-30 | 1.19e-26 | 42 |
GO:002261325 | Cervix | N_HPV | ribonucleoprotein complex biogenesis | 30/534 | 463/18723 | 2.78e-05 | 7.49e-04 | 30 |
GO:009730515 | Cervix | N_HPV | response to alcohol | 20/534 | 253/18723 | 4.14e-05 | 9.81e-04 | 20 |
GO:004225424 | Cervix | N_HPV | ribosome biogenesis | 21/534 | 299/18723 | 1.46e-04 | 2.68e-03 | 21 |
GO:000636415 | Cervix | N_HPV | rRNA processing | 14/534 | 225/18723 | 5.35e-03 | 3.84e-02 | 14 |
GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
GO:0022613 | Colorectum | AD | ribonucleoprotein complex biogenesis | 151/3918 | 463/18723 | 1.96e-09 | 1.39e-07 | 151 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0517145 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
hsa0301045 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
hsa0517155 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
hsa0301055 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
hsa03010 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa030101 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa030102 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
hsa030103 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
hsa051713 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL10A | SNV | Missense_Mutation | c.193N>C | p.Val65Leu | p.V65L | P62906 | protein_coding | tolerated(0.1) | benign(0.013) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
RPL10A | SNV | Missense_Mutation | c.519N>T | p.Lys173Asn | p.K173N | P62906 | protein_coding | tolerated(0.27) | benign(0.007) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
RPL10A | SNV | Missense_Mutation | c.497N>T | p.Ala166Val | p.A166V | P62906 | protein_coding | deleterious(0.04) | possibly_damaging(0.71) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
RPL10A | deletion | Frame_Shift_Del | c.404delC | p.Pro135LeufsTer17 | p.P135Lfs*17 | P62906 | protein_coding | TCGA-AA-3692-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | PD | |||
RPL10A | SNV | Missense_Mutation | novel | c.284A>C | p.Lys95Thr | p.K95T | P62906 | protein_coding | deleterious(0.02) | probably_damaging(0.977) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
RPL10A | SNV | Missense_Mutation | novel | c.491N>A | p.Cys164Tyr | p.C164Y | P62906 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-BG-A2L7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
RPL10A | SNV | Missense_Mutation | c.404N>T | p.Pro135Leu | p.P135L | P62906 | protein_coding | deleterious(0.03) | possibly_damaging(0.738) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RPL10A | SNV | Missense_Mutation | novel | c.644N>A | p.Arg215His | p.R215H | P62906 | protein_coding | tolerated(0.09) | benign(0.017) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
RPL10A | SNV | Missense_Mutation | c.292A>C | p.Lys98Gln | p.K98Q | P62906 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BC-A112-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
RPL10A | SNV | Missense_Mutation | novel | c.19N>G | p.Arg7Gly | p.R7G | P62906 | protein_coding | tolerated(0.4) | benign(0.015) | TCGA-DD-A1EE-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |